- Home
- NAUT vs NKTX Comparison
NAUT vs NKTX Comparison
Compare NAUT & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAUT
- NKTX
- Stock Information
- Founded
- NAUT 2016
- NKTX 2015
- Country
- NAUT United States
- NKTX United States
- Employees
- NAUT N/A
- NKTX N/A
- Industry
- NAUT Biotechnology: Laboratory Analytical Instruments
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- NAUT Industrials
- NKTX Health Care
- Exchange
- NAUT Nasdaq
- NKTX Nasdaq
- Market Cap
- NAUT 188.3M
- NKTX 170.8M
- IPO Year
- NAUT N/A
- NKTX 2020
- Fundamental
- Price
- NAUT $0.76
- NKTX $1.81
- Analyst Decision
- NAUT Hold
- NKTX Strong Buy
- Analyst Count
- NAUT 3
- NKTX 6
- Target Price
- NAUT $3.58
- NKTX $15.00
- AVG Volume (30 Days)
- NAUT 174.6K
- NKTX 2.5M
- Earning Date
- NAUT 04-29-2025
- NKTX 05-08-2025
- Dividend Yield
- NAUT N/A
- NKTX N/A
- EPS Growth
- NAUT N/A
- NKTX N/A
- EPS
- NAUT N/A
- NKTX N/A
- Revenue
- NAUT N/A
- NKTX N/A
- Revenue This Year
- NAUT N/A
- NKTX N/A
- Revenue Next Year
- NAUT N/A
- NKTX N/A
- P/E Ratio
- NAUT N/A
- NKTX N/A
- Revenue Growth
- NAUT N/A
- NKTX N/A
- 52 Week Low
- NAUT $0.66
- NKTX $1.31
- 52 Week High
- NAUT $3.09
- NKTX $8.53
- Technical
- Relative Strength Index (RSI)
- NAUT 38.87
- NKTX 54.82
- Support Level
- NAUT $0.72
- NKTX $1.67
- Resistance Level
- NAUT $0.83
- NKTX $1.84
- Average True Range (ATR)
- NAUT 0.11
- NKTX 0.14
- MACD
- NAUT 0.02
- NKTX 0.03
- Stochastic Oscillator
- NAUT 39.20
- NKTX 68.42
About NAUT Nautilus Biotechnolgy Inc.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.
About NKTX Nkarta Inc.
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.